Falk takes on Lipid's ulcerative colitis lead in EU while search for US partner goes on
This article was originally published in Scrip
Dr Falk Pharma has formally exercised its option on Lipid Therapeutics' lead product, LT-02, for ulcerative colitis. The German companies signed a co-development and option-agreement in 2009. Falk is now assuming full responsibility for the further development and commercialisation of LT-02 in Europe, with a Phase III induction trial in ulcerative colitis planned to start in the second half of 2012.